MEMOTEXT and Vanderbilt University Medical Center announce co-commercialization of a validated, accessible digital SMS text engagement program for at-risk Type 2 Diabetes populations.
Toronto, October 31, 2022 – MEMOTEXT Corporation and Vanderbilt University Medical Center (VUMC) have successfully reached an agreement to make the Rapid Education And Communications for Health (REACH) text messaging program commercially available. The REACH program validated in a long–term study provides support, education, encouragement and evidence-based content via automated, interactive text messaging to underserved and diverse patient groups for type 2 diabetes.
Adherence to medication and the recommended self-care activities for managing type 2 diabetes has traditionally been suboptimal and can increase disease complexity, onset of retinopathy, end-stage renal disease and other complications. According to the CDC, only 23.8% of adults with diabetes met the recommended goals of physical activity per week and 56.8% of adults between the ages of 40 and 75 were on recommended statin therapy.i REACH sends an individually tailored program on type 2 diabetes designed to support patients’ self-care, adherence and improve HbA1c. Messages are personalized based on a patient’s specific barriers preventing them from managing their diabetes. Amos Adler, founder of MEMOTEXT says, “Diabetes is a disease that affects so many and has major impacts on healthcare burden. We are honored to partner with VUMC to make the REACH program available to help adults manage the complexities of this condition.”
Results from validation showed enhanced awareness about nonadherence, increased accountability and improved medication adherence. Patients show high satisfaction and a 91% response rate to interactive text messages. Bringing this accessible tool to the health plans, PBMs and providers allows MEMOTEXT and VUMC to extend the benefits of the REACH program and help more individuals with type 2 diabetes. “We are excited to make this theory-based, validated digital texting program available to health systems and stakeholders as evidence grows that texting programs show efficacy in adherence and outcomes” says Lindsay Mayberry, PhD, Associate Professor of Medicine and Biomedical Informatics at VUMC, and Principal Investigator for the application.
To read more about the methods and outcomes of the study visit: Development and Usability of REACH: A Tailored Theory-Based Text Messaging Intervention for Disadvantaged Adults With Type 2 Diabetes – PMC (nih.gov) and Effects of a Tailored Text Messaging Intervention Among Diverse Adults With Type 2 Diabetes: Evidence from the 15-Month REACH Randomized Controlled Trial
Trusted since 2012, MEMOTEXT is a platform for co-creation of digital patient engagement communications, MEMOTEXT uses health data to drive personalization of digital adherence, care-coordination and support applications. MEMOTEXT enables academics/clinicians and commercial partners to co-create interactive, adaptive, evidence-based engagement communications and digital therapeutics (DTx). Together they (co)commercialize those interventions with their provider, insurer and pharmaceutical clients on the MEMOTEXT Marketplace.